There are no announcements yet.
Disease Description
Squamous cell carcinoma (SCC) is an uncontrolled growth of abnormal cells arising in the squamous cells. Squamous cells are cells which compose most of the skin’s upper layers . SCCs often look like scaly red patches, open sores, elevated growths with a central depression, or warts; they may crust or bleed. SCC is mainly caused by cumulative UV exposure over the course of a lifetime. It can become disfiguring and sometimes deadly if allowed to grow. [1]
Prevalance
An estimated 700,000 cases of SCC are diagnosed each year in the US, and about two percent of all SCC – up to 8,800 people – died from the disease in the US in 2012. [1]
Current Treatment Options
For superficial low-risk Squamous Cell Carcinoma lesions treatment options include surgical excision, or topical treatment with topical 5-fluorouracil or imiquimod. Squamous cell carcinomas usually remain confined to the epidermis (the top skin layer) for some time. However, the larger these tumors grow, the more extensive the treatment needed. They eventually penetrate the underlying tissues, which can lead to major disfigurement, sometimes even the loss of a nose, eye or ear. A small percentage — estimates run from 2 to almost 10 percent - spread (metastasize) to distant tissues and organs. When this happens, squamous cell carcinomas frequently can be life-threatening. [1]
Evidence for and Proposed Mechanism for Cannabinoid Therapies
Accumulating recent evidence implicates the endocannabinoid system in the regulation of growth of skin cells. Casanova et al. have demonstrated that various human skin tumors (e.g. basal cell carcinoma, squamous cell carcinoma) express cannabinoid receptors both CB1 and CB2. Local administration of synthetic CB1 and CB2 agonists induced growth inhibition of malignant skin tumors in mice. This growth inhibition was accompanied by enhanced intra-tumor cell death and impaired tumor vascularization (altered blood vessel morphology, decreased expression of pro-angiogenic factors such as VEGF, placental growth factor and angiopoietin 2) [2]
1. Skin Cancer Foundation. www.skincancer.org/
2. Pacher, P. et al. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. Aug 2009; 30(8): 411–420.
Recent GBXI News:
May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets
April 21, 2023, GBX International Group, Inc., (OTC: GBXI)
HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
I hope everyone is doing well. Raymond, Francis Cormier wrote a very detailed, informative summery over a month ago. I do not believe his 4 ever...I hope everyone is doing well. Raymond, Francis Cormier wrote a very detailed, informative summery over a month ago. I do not believe his 4 ever important questions have been answered.
(1) Who's working on updating documentation? What's the % complete?
(2) Who owns and/or controls the CBIS Intellectual Property?
(3) is there another entity out there using the same name as Cannabis Science?
(4) WHERE IS BRINGING CBIS BACK PUBLIC AGAIN ON YOUR LIST OF PRIORITIES?
Can you please elaborate on these for us.
Show more
Hi Raymond,
Per the 3rd party Cancer Drug Valuation(s) Full Report linked from this website:
On November 8, 2023; Capizate, Inc. (a 3rd party entity)...Hi Raymond,
Per the 3rd party Cancer Drug Valuation(s) Full Report linked from this website:
On November 8, 2023; Capizate, Inc. (a 3rd party entity) reported a "Situation Analysis of GBXi" that it performed at GBXI's request; based upon 25 documents provided by GBXI; mostly pertaining to Cannabis Science, Inc. This report included listing: (a) Strengths, (b) Areas for Improvement, (c) CBIS Cancer Drug Valuation(s) [1 specifically], (d) as well as several additional items that supported it giving GBXI a Capitize Score = 623 out of a possible 1000. Getting the potential CBIS Drug Valuation(s) for just 1 drug @ 25Mil-29Mil is/was impressive; however the "Areas for Improvement" are significant:
Areas for improvement
---------------------
1. The business documents, agreements, term sheets, engagements are all dated in 2017-2018 and need to be updated.
2. Ownership and control of the intellectual property needs to be defined and confirmed.
3. A similar entity has active registration with California Secretary of State. The Company has a different address than on the Company website and also had a Statement of Info due to the California Secretary of State on 05/10/2023. Registered with the California Secretary of State as a Non-Profit Nonprofit Corporation - CA - Mutual Benefit. This will need to be defined.
Can you please let us know about the progress that has been made toward resolving these issues?? Even if you could reveal an estimated % complete for each line item that would be nice to see.
The report from November 8, 2023 says: "Your current phase in our process is phase three (Situation Analysis), four (Due Diligence Score), and five (Business Finance Documents – Specifically the analysis) the potential valuation" - out of a 7 phase process; (6) Capital Markets and (7) Post Capitalization. Even if you choose not to continue to use Capitize, Inc. any longer; these "Areas of Improvement" listed MUST BE addressed in order to bring CBIS back Trading again.
Thank you in advance of your response and Best Regards,
...Francis G. Cormier III
Show more
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
"We Own everything we speak about Owning,... Show more yesterday
Now that I'm past that NASTY Sickness phase we can... Show more yesterday